Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 16205738.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We assessed the efficacy and safety of 10-d monotherapy with the orally administered CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of CXCR4-using virus. Maximum reduction in viral load occurred at a median of 10-15 d, with a mean reduction of >or=1.6 log(10) copies/ml at all twice daily doses >or=100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach.
Medical subject headings
- Anti-HIV Agents
- CCR5 Receptor Antagonists
- Clinical Trials, Phase II as Topic
- HIV Infections
- HIV-1
- Randomized Controlled Trials as Topic